Advanced Chart
  • Wed, Sep. 21, 9:23 AM
    • First Trust Morningstar Dividend Leaders Index Fund (NYSEARCA:FDL) - $0.201.
    • First Trust US IPO Index Fund (NYSEARCA:FPX) - $0.073.
    • First Trust Capital Strength ETF (NASDAQ:FTCS) - $0.103.
    • First Trust Total US Market AlphaDEX ETF (NASDAQ:TUSA) - $0.067.
    • First Trust Value Line Dividend Index Fund (NYSEARCA:FVD) - $0.126.
    • First Trust S&P REIT Index Fund (NYSEARCA:FRI) - $0.093.
    • First Trust ISE Water Index Fund (NYSEARCA:FIW) - $0.050.
    • First Trust ISE-Revere Natural Gas Index Fund (NYSEARCA:FCG) - $0.021.
    • Payable Sept. 30; for shareholders of record Sept. 23; ex-div Sept. 21.
    • Press Release
    | Wed, Sep. 21, 9:23 AM
  • Mon, Aug. 29, 3:00 AM
    • A flood of share debuts is expected to invigorate the listless IPO market after the coming Labor Day holiday.
    • On the radar: Valvoline (Pending:VVV), Nutanix (Private:NTNX), Bank of N.T. Butterfield & Son, J.A. Cosmetics US and Yeti Holdings (Pending:YETI).
    • As of late August, 2016 was on track to be the worst year for IPOs since the financial crisis, with 63 companies listing on U.S. exchanges and raising just $12.9B.
    | Mon, Aug. 29, 3:00 AM | 2 Comments
  • Mon, Aug. 8, 12:47 PM
    • The IPO market could be poised to heat up after a very slow first half of the year. The number of companies going public was at a seven-year low in Q1 and was still below average in Q2 despite some improvement.
    • Analysts think that the solid average returns on this year's batch of IPOs and a strong debut for Twilio in the tech sector is on the verge of breaking the "logjam" of companies stuck in a holding pattern.
    • Some of the notable names floating out there include Uber (Private:UBER), Snapchat (Private:CHAT), Airbnb (Private:AIRB), Neiman Marcus (Pending:NMG), Univision (Pending:UVN), SoulCycle (Pending:SOULC), and Pinterest (Private:PINIT).
    • Related ETFs: IPO, IPOS, FPX, FPXI.
    | Mon, Aug. 8, 12:47 PM | 2 Comments
  • Sat, May 21, 1:42 PM
    • Tech IPOs are missing in action this year as Silicon Valley startups continue to raise capital through private investors.
    • In a recent survey, only 17% of Silicon Valley companies indicated that an IPO was a goal, while at SWSX the percentage of tech executives that answered "no way" to an IPO plan was all the way up to 42%.
    • Extra costs and the pressure to meet quarterly estimates are two major factors in the aversion to the public route from the sector.
    • Uber (Private:UBER) CEO Travis Kalanick summed up the stance when he told CNBC that he aimed for his company to have an IPO as late as possible.
    • Related ETFs: IPO, IPOS, FPX, FPXI.
    | Sat, May 21, 1:42 PM | 6 Comments
  • Tue, Mar. 22, 4:51 AM
    • Global IPO activity volume fell nearly 40% to just over $12B in the first quarter, marking its weakest start to the year since the financial crisis.
    • Lower oil and commodity prices, the strength of the U.S. dollar and economic volatility has led investors to adopt a "wait and see" approach or seek alternatives such as M&A, according to EY's latest Global IPO Trends report.
    • Executive Director Martin Steinbach adds that the slowdown is evident in all regions across the world, but that it's important to note that there is still, on average, one IPO each day.
    | Tue, Mar. 22, 4:51 AM
  • Fri, Feb. 26, 2:59 PM
    • No IPOs priced this week to mark the sixth week of the year with no activity.
    • Only four IPOs have made it to market for combined proceeds of just $436M, notes market intelligence firm Ipreo Capital Markets.
    • The IPO class of 2015 isn't faring well through the volatile market. Through the end of last week, the 170 IPOs from last year average a -22% return (-31% aftermarket return). 74% of the 2015 IPO stocks trade below their issue price.
    • Related ETFs: IPO, IPOS, FPX, FPXI.
    | Fri, Feb. 26, 2:59 PM
  • Fri, Feb. 19, 3:47 AM
    • Of the almost 175 companies that made their U.S. stock-market debuts in 2015, more than 70% are now trading below their IPO prices (on average their shares are down about 20%).
    • A downturn in investor sentiment, which began gradually last summer then suddenly became severe earlier this year has been felt hardest by the market's newest companies, creating a hostile environment for new IPOs.
    • There were no U.S. initial public offerings in January, and there have been only four new listings this month.
    • Related tickers: FDC, TEP, CPPL, RACE, UNVR, FIT, FPX, IPO, IPOS, FPXI
    | Fri, Feb. 19, 3:47 AM | 8 Comments
  • Wed, Feb. 3, 11:44 AM
    • The IPO market is off and running after taking the month of January off.
    • Chinese biotech BeiGene (NASDAQ:BGNE) priced its offering at $24 (high end of range) and Editas Medicine (NASDAQ:EDIT) priced at $16 (low end).
    • Both stocks are up solidly in opening trading.
    • Last night, Petco Holdings officially pulled its IPO due to a private equity buyout.
    • Previously: Crickets in the IPO market (Jan. 29 2016)
    • Related ETFs: IPO, IPOS, FPX, FPXI.
    | Wed, Feb. 3, 11:44 AM | 1 Comment
  • Fri, Jan. 29, 2:37 PM
    • January is just hours away from being the first month since September of 2011 that no new issuer has come to the IPO market, notes Ipreo Capital Markets.
    • The only recent activity has been Ballast Point pulling its IPO after being acquired and AmeriQuest postponing an offering due to market instability.
    • Related ETFs: IPOS, FPXI, FPX, IPO.
    | Fri, Jan. 29, 2:37 PM | 1 Comment
  • Wed, Jan. 20, 8:29 AM
    • The IPO market has been relatively quiet for the first two weeks of 2016 amid market turmoil as a number of companies on the IPO watch list (Univision, Neiman Marcus, Albertsons) remain in a holding pattern for their official filing. No deals price this week and no deals over $300M are expected for the next two per Ipreo Capital Markets.
    • A risk-off sentiment has hurt the Renaissance IPO ETF (NYSEARCA:IPO) which has doubled the loss of the S&P 500 so far this year with a 15% drop.
    • Related ETFs: FPX, IPOS, FPXI.
    | Wed, Jan. 20, 8:29 AM
  • Dec. 23, 2015, 10:49 AM
    • Renaissance Capital reports that 169 IPOs raised $30B in 2015 to mark a six-year low for IPO action. Last year, 275 deals generated over $85B in proceeds.
    • The biotech sector was one of the only pockets of high IPO activity during a very weak second half of the year. Tech IPOs were downright scarce, with proceeds down 87% Y/Y.
    • The average aftermarket return of -15.4% is the worst performance for IPOs since 2011.
    • Notable IPOs on file for a potential 2016 debut include Neiman Marcus Group (Pending:NMG), Univision (Pending:UVN), Albertsons (NYSE:ABS), Vizio, SoulCycl (OTCQB:SOUL), and Station Casinos. Most analysts don't expect Federal Reserve rate increases to be a huge factor as companies weigh when to file.
    • An IPO watchlist from Renaissance Capital of private companies includes Uber (Pending:UBER), Dropbox (Pending:DROPB), US Foods, MGM Growth Properties (MGM's REIT), and Airbnb (Pending:AIRB).
    • Related ETFs: FPX, IPO, IPOS, FPXI.
    | Dec. 23, 2015, 10:49 AM
  • Mar. 25, 2015, 2:45 PM
    • Kraft is the 2nd-largest holding in the PowerShares Dynamic Food & Beverage ETF's (PBJ +1.9%) 31 stocks.
    • Others getting a lift include the Guggenheim Spin-Off ETF (CSD +1.5%), and the First Trust IPO Index (FPX +0.8%),.
    • Source: Barron's
    • Previously: Kraft, Heinz announce merger (March 25)
    | Mar. 25, 2015, 2:45 PM
  • Nov. 5, 2014, 1:27 PM
    • The First Trust Emerging Markets Local Currency Bond ETF (NASDAQ:FEMB) is an active fund that seeks to maximize total return and income, while also minimizing volatility, by investing in bonds that are denominated in the issuer's local currency.
    • Another active fund, the First Trust Low Duration Mortgage Opportunities ETF (NASDAQ:LMBS) will invest at least 80% of its net assets in investment-grade, mortgage-related debt securities and other mortgage-related instruments in the search of current income for investors.
    • The third fund launched by the group today was the First Trust International IPO ETF (NASDAQ:FPXI), which tracks a basket of the 50 largest and typically most liquid companies that are domiciled outside the U.S. within the IPOX Global Composite Index.
    • Other emerging market bond ETFs: EMB, PCY, ELD, EMLC, VWOB, LEMB, EMAG, EBND, EMSH
    • Other mortgage REIT ETFs: REM, MORL, MORT
    • Other IPO ETFs: FPX, IPO, IPOS
    | Nov. 5, 2014, 1:27 PM
  • Oct. 7, 2014, 12:46 PM
    • Like the Renaissance IPO ETF (NYSEARCA:IPO), the Renaissance International IPO ETF (NYSEARCA:IPOS) tracks an index of newly public companies, with the twist of selecting only international funds.
    • Since launching just under a year ago, IPO has returned 12.5% to investors, recovering after a difficult spring for the fund.
    • The only other ETF covering recent IPOs is the First Trust IPOX Index ETF (NYSEARCA:FPX), which launched in 2006 and only covers domestic firms; this makes IPOS the first ETF in the international IPO niche. 
    | Oct. 7, 2014, 12:46 PM | 5 Comments
  • Apr. 17, 2014, 11:02 AM
    • TriVascular Technologies (TRIV +12%) holds onto its gain from yesterday's debut that ended at $13.79 (+14.9%) on turnover of 2.2M shares. Volume thus far in today's trading is light at 63K, however.
    • The medical device maker's lead product is its Ovation System, an endovascular stent graft for the repair of an abdominal aortic aneurysm. It received CE Mark approval in August 2010 and FDA approval in October 2012. Commercial sales began in the U.S. in November 2012.
    • Revenues for 2012 and 2013 were $5.4M and $19.5M, respectively.
    • Gross profit was -$3.6M and $7.8M.
    • Net loss was -$43.3M and -$50.3M.
    • Net loss/share was -$5.89 and -$5.01.
    • CF Ops was -$34M and -$46.9M.
    • Prospectus
    • (IPO) (FPX)
    | Apr. 17, 2014, 11:02 AM
  • Apr. 14, 2014, 1:34 PM
    • In yet another example of the recent struggles of biotechs, recent IPO Adamas Pharmaceutics (ADMS +2.8%) exchanges hands for $13.40/share, down 16% from its initial price of $16 and down 22% from its opening day high of $17.24.
    • The company generates its revenues from collaboration and licensing deals but has two compounds in development that it plans to sell directly.
    • ADS-5102 (amantadine) is a treatment for levadopa-induced dyskinesia, a movement disorder in Parkinson's sufferers after long term exposure to levadopa. A Phase 3 clinical trial will start this year. The company forecasts its NDA submission to happen in the first half of 2016.
    • ADA-8704 is a once-daily combination of Namenda XR (memantine HCL) and donepezil HCL for moderate to severe dementia in Alzheimer's patients. The NDA has been submitted to the FDA triggering a $40M milestone payment from partner Forest Labs (FRX +0.1%).
    • Revenues for 2012 and 2013 were $37.5M and $71.1M, respectively.
    • Net income was $17.7M and $50.9M, respectively.
    • CF Ops was $52M and $26.8M, respectively.
    • (IPO) (FPX)
    | Apr. 14, 2014, 1:34 PM
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub